Market closedNon-fractional
Anixa Biosciences/ANIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Anixa Biosciences
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
Ticker
ANIX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
San jose, United States
Employees
4
Website
www.anixa.com
ANIX Metrics
BasicAdvanced
$78M
Market cap
-
P/E ratio
-$0.35
EPS
0.85
Beta
-
Dividend rate
Price and volume
Market cap
$78M
Beta
0.85
52-week high
$5.13
52-week low
$2.40
Average daily volume
2.3
Financial strength
Current ratio
15.192
Management effectiveness
Return on assets (TTM)
-40.49%
Return on equity (TTM)
-41.01%
Return on investment (TTM)
-41.26%
Valuation
Price to revenue (TTM)
369.126
Price to book
3.136
Price to tangible book (TTM)
3.15
Growth
Earnings per share change (TTM)
12.82%
What the Analysts think about ANIX
Analyst Ratings
Majority rating from 1 analysts.
ANIX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$3.2M
23.08%
Profit margin
0.00%
NaN%
ANIX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.07
-$0.08
-$0.09
-$0.10
-
Expected
-$0.12
-$0.09
-$0.09
-$0.09
-$0.11
Surprise
-39.13%
-11.11%
0.00%
11.11%
-
ANIX News
AllArticlesVideos
Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy
PRNewsWire·4 days ago
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
PRNewsWire·1 week ago
Anixa Biosciences Announces $5 Million Share Repurchase Program
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anixa Biosciences stock?
Anixa Biosciences (ANIX) has a market cap of $78M as of July 27, 2024.
What is the P/E ratio for Anixa Biosciences stock?
The price to earnings (P/E) ratio for Anixa Biosciences (ANIX) stock is 0 as of July 27, 2024.
Does Anixa Biosciences stock pay dividends?
No, Anixa Biosciences (ANIX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Anixa Biosciences dividend payment date?
Anixa Biosciences (ANIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Anixa Biosciences?
Anixa Biosciences (ANIX) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Anixa Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.